Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning, all! Today, we talk about the future of the BIOSECURE Act, layoffs at Recursion, and more. We’ll be taking off the rest of the week in observance of that holiday where everyone goes full-on glutton and online shops, so we’ll see you bright and early Monday.
BIOSECURE Act may be at a make-or-break moment
We’re coming up on a pivotal moment for the BIOSECURE Act. The legislation, which would restrict U.S. companies from working with certain Chinese companies for contract manufacturing and other important services,
must be passed by Congress by December in order to sidestep some major obstacles. Perhaps the primary one: The bill faces opposition from Sen. Rand Paul (Ky.), who is set to chair the Homeland Security and Governmental Affairs Committee in the Republican-led Senate next year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
